Topical MAPK Inhibition in Rosacea

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: 1

Phase: PHASE1

Enrollment: 20

Sponsor: Albany Research Institute, Inc.

Summary

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Eligibility Criteria

Inclusion Criteria:Erythematotelangiectatic rosacea diagnosed by a clinician in the centrofacial and/or ocular regions.Exclusion Criteria:Other concurrent diseases for which treatment is being received that would preclude the use of trametinib (i.e., pleural effusion, active infection, intracranial bleeding)History of skin allergic reactions or documented allergic reaction to trametinibPregnancy or lactation.Heart failure or other heart diseaseActive use of medications with known documented interactions with trametinib (Chloroquine, Ritonavir, Loperamide, Penicillamine)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05616923). StuddyBuddy aggregates publicly available trial information.